Hence, we used the NLRP3 inhibitor-MCC950 and combined it with calycosin in IBD model mice to observe the efficacy of such a combination therapy in treating intestinal interstitial fibrosis. The gene discussed is NLRP3; the disease is inflammatory bowel disease.